Fractures ‐ not reported · patients with Duchenne muscular dystrophy
1 finding from 1 review
Prolongation of time to loss of ambulation ‐ not reported · patients with Duchenne muscular dystrophy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Muscle strength ‐ not reported · patients with Duchenne muscular dystrophy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in 10‐metre walking time · patients with Duchenne muscular dystrophy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in 4‐stair climbing time · patients with Duchenne muscular dystrophy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Weight gain · patients with Duchenne muscular dystrophy
1 finding from 1 review
Behavioural changes · patients with Duchenne muscular dystrophy
It is very uncertain whether deflazacort changes behavioural changes compared with prednisone (very low certainty).
1 finding from 1 review
Fracture · patients with Duchenne muscular dystrophy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Prolongation of time to loss of ambulation ‐ not reported · patients with Duchenne muscular dystrophy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life (AQLQ) · adults with asthma
1 finding from 1 review
Intervention not reported
Serious adverse events 49 weeks · adults with asthma
The intervention showed no clear difference in serious adverse events 49 weeks (low certainty).
1 finding from 1 review
Intervention not reported
Exacerbations requiring hospital admission 49 weeks · adults with asthma
The intervention showed no clear difference in exacerbations requiring hospital admission 49 weeks (low certainty).
1 finding from 1 review
Intervention not reported
Lung function (change in trough FEV1 L) · adults with asthma
1 finding from 1 review
Intervention not reported
Asthma control (ACQ) · adults with asthma
1 finding from 1 review
Intervention not reported
Any adverse events 49 weeks · adults with asthma
The intervention leads to lower any adverse events 49 weeks (high certainty).
1 finding from 1 review
Intervention not reported
Mortality · acute bacterial meningitis
The intervention showed no clear difference in mortality (moderate certainty).
1 finding from 1 review
Intervention not reported
Severe hearing loss · acute bacterial meningitis
The intervention leads to lower severe hearing loss (high certainty).
1 finding from 1 review
Intervention not reported
Any hearing loss · acute bacterial meningitis
The intervention leads to lower any hearing loss (high certainty).
1 finding from 1 review
Intervention not reported
Short‐term neurological sequelae · acute bacterial meningitis
The intervention showed no clear difference in short‐term neurological sequelae (high certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ recurrent fever · acute bacterial meningitis
The intervention probably leads to higher adverse events ‐ recurrent fever (moderate certainty).
1 finding from 1 review